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Introduction: This phase 1 study was conducted to determine the
recommended phase 2 dose of the selective insulin-like growth factor
type 1 receptor (IGF-IR) inhibitor figitumumab (F, CP-751,871) given
in combination with paclitaxel and carboplatin in patients with ad-
vanced solid tumors.
Methods: Patients received paclitaxel 200 mg/m2, carboplatin (area
under the curve of 6), and F (0.05–20 mg/kg) q3 weeks for up to six
cycles. Patients with objective response or stable disease were
eligible to receive additional cycles of single agent F until disease
progression. Safety, efficacy, pharmacokinetic, and pharmacody-
namic endpoints were investigated.
Results: Forty-two patients, including 35 with stages IIIB and IV
non-small cell lung cancer (NSCLC), were enrolled in eight dose
escalation cohorts. A maximum tolerated dose was not identified.
Severe adverse events possibly related to F included fatigue, diar-
rhea, hyperglycemia, gamma glutamyl transpeptidase elevation, and
thrombocytopenia (one case each). F plasma exposure parameters
increased with dose. Fifteen objective responses (RECIST) were
reported, including two complete responses in NSCLC and ovarian
carcinoma. Notably, levels of bioactive IGF-1 seemed to influence
response to treatment with objective responses in patients with a
high baseline-free IGF-1 to IGF binding protein-3 ratio seen only in
the 10 and 20 mg/kg dosing cohorts.
Conclusions: F was well tolerated in combination with paclitaxel
and carboplatin. Based on its favorable safety, pharmacokinetic, and
pharmacodynamic properties, the maximal feasible dose of 20
mg/kg has been selected for further investigation.
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The insulin-like growth factor (IGF) system comprised theIGF ligands (IGF-1 and IGF-2), the IGF binding proteins
(IGFBPs 1–6) that regulate their bioactivity, and the cell
surface receptors IGF-1R and IGF-2R.1 Signaling through the
IGF-1R plays important roles in normal growth and devel-
opment and in cancer progression.1 In NSCLC, the IGF-1R
has been shown to be frequently expressed in tumor tissue
and to mediate the proliferation of lung cancer cell lines.2
Also, high IGF-1 and low IGFBP-3 levels have been associ-
ated with a higher incidence and severity of the disease.3
These data suggest that targeting the IGF-1R could be a
viable approach in the treatment of NSCLC.
Figitumumab (F) is a selective inhibitor of the IGF-1R,
which has been well tolerated in initial studies. F increases
the tumor growth inhibition activity of chemotherapy and
targeted agents in preclinical models.4 This phase 1b study
was conducted to define the recommended phase 2 dose
(RP2D) of F when given in combination with standard doses
of paclitaxel and carboplatin in patients with advanced solid
tumors.
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PATIENTS AND METHODS
Patient Selection
Patients with advanced tumors in whom the combina-
tion of paclitaxel and carboplatin was a reasonable treatment
option were candidates for this study. Additional eligibility
criteria included: age 18 years; Eastern Cooperative Oncol-
ogy Group performance status 1; recovery from any prior
treatment toxicity to the National Cancer Institute Common
Terminology Criteria for Adverse Events version 3.0 (CT-
CAE 3.0) grade 1; adequate hematopoietic (ANC 1500/
L, platelets 100,000/L), hepatic (total bilirubin 1.5
normal, aspartate aminotransferase and alanine aminotrans-
ferase 5 times normal), and renal (serum creatinine 1.5
times normal or calculated creatinine clearance 60 mL/min)
function; serum albumin 2.7 g/dl; 12-lead electrocardiogram
with normal tracing, or nonclinically significant changes that
would not require medical intervention. Enrollment exclu-
sions included evidence of moderate or severe mitral valve
regurgitation on transthoracic Doppler echocardiogram; fe-
males of childbearing potential who refused adequate meth-
ods of contraception; active gastrointestinal abnormalities;
symptomatic brain metastasis (patients with brain metastases
were enrolled if stable); coexisting uncontrolled medical
condition; neuropathy grade 1; known hypersensitivity to
Cremophor; and major surgical procedure or radiation ther-
apy within 4 weeks or 1 week, respectively, before study drug
administration. The protocol was conducted in accordance
with Good Clinical Practice guidelines. All patients provided
written informed consent.
Study Design and Treatment Plan
The primary objective of the study was to determine the
RP2D of F in combination with standard doses of paclitaxel
and carboplatin. Toxicities were assessed using the National
Cancer Institute CTCAE 3.0. Dose-limiting toxicities (DLTs)
included grade 4 treatment-related neutropenia (ANC
500 cells/mm3) lasting 7 days, complicated by fever
and/or requiring hospitalization; grade 4 thrombocytopenia
(platelets 25,000 cells/ mm3); grade 3 gastrointestinal
toxicity despite optimal intervention and/or prophylaxis; any
other F-related grade 3 nonhematological toxicity; and any
structural and/or functional changes in transthoracic Doppler
echocardiography parameters. Patients received paclitaxel
200 mg/m2 intravenously (IV) more than 3 hours and carbo-
platin at an area under the curve (AUC) of 6, IV more than 15
to 60 minutes every 3 weeks. In the original protocol, F was
administered IV after chemotherapy administration at doses
of 0.05 to 10 mg/kg according a dose-doubling dose escala-
tion schema.5 Based on the favorable safety profile of F in
three ongoing dose escalation trials,6,7 this study protocol was
amended to omit the 0.2 and 0.4 mg/kg F dose escalation
cohorts, and only two patients were enrolled at the 0.1 mg/kg
dosing cohort. Furthermore, based on the favorable safety and
tolerability profile observed at the 10 mg/kg cohort, an
additional cohort investigating the F dose of 20 mg/kg was
introduced by protocol amendment. A dose of 30 mg/kg
given every 3 weeks as a single agent was investigated in
another study, not yet reported, and found to be not well
tolerated. Consequently, doses higher than 20 mg/kg were not
considered for testing in this study. Patients were eligible to
receive up to six cycles of chemotherapy combined with F
unless disease progression or unacceptable toxicity devel-
oped. On completion or early discontinuation of chemother-
apy, patients were eligible to receive additional cycles of
single agent F at a dose found to be well tolerated in two
phase I dose escalation studies of single agent F conducted in
parallel to this trial.6,7 To open a new dosing cohort, one
patient in the previous cohort had to complete at least 3
weeks, and two additional patients at least 2 weeks, of safety
follow-up without identification of DLTs. The 10 and 20
mg/kg cohorts were empirically extended to 17 and 7 pa-
tients, respectively, to obtain further safety and pharmacody-
namic information.
Safety Parameters
Before enrollment, at each treatment visit and either at
the completion of the study or premature discontinuation,
patients underwent safety laboratory testing (blood chemis-
try, hematology, and urinalysis) and were queried for adverse
events and concomitant medication use. Doppler echocardio-
grams were recorded at baseline, end of cycles 1 and 6, or at
premature discontinuation. Plasma samples for detection of
antidrug antibodies were collected at baseline, end of cycles
1 and 6, and 150 days from the last F infusion.
TABLE 1. Demographics Characteristics
























a Histologies other than NSCLC includeovarian carcinoma stage IIIC (n  1);
colorectal carcinoma stage IV (1); hormone refractory prostate cancer (1); and hepato-
cellular carcinoma (1).
ECOG PS, Eastern Cooperative Oncology Group performance status; NOS, not
otherwise specified.
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Pharmacokinetics
All patients had pharmacokinetic (PK) blood sam-
ples taken 30 minutes before each infusion,1 hour after the
end of infusion during cycles 1 to 4, and 1, 3, and 7 days
after the end of infusion at cycles 1 and 4. Additionally, PK
samples were collected 30 minutes before infusion in cycles
5 and 6, at the end of study, and at 150 days after the last F
dose. Plasma concentrations of F were analyzed as described
previously.7
Pharmacodynamics
Biomarkers investigated included the enumeration of
circulating tumor cells (CTCs), CTCs expressing the IGF-1R
and circulating endothelial cells (CECs).8 Additional biomar-
kers included the measurement of plasma levels of the circu-
lating cleaved soluble IGF-1R extracellular domain (sIGF-
1R), free (bioactive) IGF-1 (fIGF-1), and IGF binding protein
3 (IGFBP-3) using enzyme linked immune assays (DSL,
Webster, TX). Blood samples for the determination of CTCs
and serum markers were collected before dosing at each
treatment cycle. Additional samples were collected on day 8
and at the end of the study.
Clinical Responses
Tumor assessments were conducted at baseline and
repeated every 6 weeks until disease progression. Disease
status was assessed by investigator according to RECIST.
RESULTS
Patient Characteristics
A total of 43 patients were enrolled between February
2005 and December 2007. One patient discontinued protocol
before receiving treatment. The rest of the patients received F
alone or in combination with paclitaxel and carboplatin for a
median of five cycles. Demographic characteristics, perfor-
mance status, disease stage, and tumor histologies are de-
scribed in Table 1. Table 2 summarizes the treatments ad-
ministered. No apparent dose-effect of F on the cumulative
dose of chemotherapy was observed. Two study discontinu-













0.05a 3 10 2 to 68 1175 7–37,644
0.1b 2 5 4–7 259 30–489
0.8c 4 3 2–9 277 54–95
1.5 3 1 1–4 142 129–416
3d 3 7 2–9 2490 288–3118
6c 3 3 1–10 1754 362–11,115
10 17 6 1–12 3188 470–8018





0.05 3 6 2–6 — —
0.1 2 5 4–6 1785 1400–2170
0.8 4 3 2–6 1418 397–2132
1.5 3 1 1–4 406 366–1460
3 3 3 2–6 1124 536–1988
6 3 3 1–6 1234 342–1240
10 17 5 1–6 1510 300–2632





0.05 3 6 2–6 5232 1,680–6025
0.1 2 5 4–6 3197 2985–3410
0.8 4 3 1–6 1972 642–3600
1.5 3 1 1–4 750 603–3000
3 3 3 2–6 1634 715–3289
6 3 3 1–5 2310 869–4475
10 17 5 1–6 2591 540–5946
20 7 4 1–6 2303 660–4456
a One patient received maintenancetherapy with F single agent at 3 mg/kg (eight cycles) and 10 mg/kg (54 cycles).
b One patient received maintenancetherapy with F at 6 mg/kg.
c One patient received maintenancetherapy with f at 10 mg/kg.
d Two patients received maintenancetherapy with F at 10 mg/kg.
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ations due to combined treatment were reported and are de-
scribed later. Paclitaxel was dose reduced in seven patients, six
at the 10 mg/kg cohort (n 17), and one at the 20 mg/kg cohort
(n  7). Carboplatin was dose reduced in three patients, two at
the 10, and one at the 3 mg/kg (n  3) dosing cohorts. Dose
reductions were attributed to neutropenia, weight loss, and
creatinine increase. Seventeen patients received single agent
F on discontinuation of chemotherapy. Median and range of
F single agent therapy were three and 1–62 cycles, respec-
tively. One patient has received a total of 68 cycles, approx-
imately 4 years, of F treatment (Table 2).
Safety Profile
One patient died of disease progression while receiving
study treatment with chemotherapy and 20 mg/kg of F. Table
3 summarizes all adverse events with a frequency higher than
5% and any CTCAE grade 3 event reported by investigator
as possibly related to F. Seventy-one adverse events possibly
related to F were reported in 28 study subjects. Five of these
events were grade 3 and included fatigue, diarrhea, hypergly-
cemia, gamma glutamyl transpeptidase (GGT) elevation, and
thrombocytopenia (one case each). All of them were reported
in patients enrolled in the 10 mg/kg dosing cohort. The grade
3 events of GGT elevation and thrombocytopenia were at-
tributed to the combination regimen and resulted in treatment
discontinuation. The event of hyperglycemia was manageable
with antidiabetic medication. No DLT was reported at the 20
mg/kg cohort. Grade 2 events included arthralgia, weight
loss, and anemia. Cardiac function was monitored using
Doppler echocardiogram. Ninety-one Doppler echocardio-
grams were conducted without treatment related findings
reported. No quantifiable antidrug antibodies were detected.
PK Analysis
F plasma concentration-time data were available from
40 patients. One patient was excluded from the analysis
because of incomplete data. Plasma concentrations of F
decreased in a multiexponential manner after intravenous
infusion (Figure 1). As shown in Table 4, the plasma con-
centration at the end of infusion (C1 hour) and the AUC within
a cycle (AUC0–day 22) increased with dose at both cycles 1
and 4. The increase in AUC0–day 22 was approximately dose
proportional at dose levels higher than 0.8 mg/kg. After
repeated administration every 3 weeks, there was a moderate
accumulation in plasma exposure of F at dose levels 3
mg/kg. Mean accumulation ratio reached approximately two-
fold at 10 and 20 mg/kg q3 weeks dosing (Figure 1 and Table
4), supporting an effective half-life approximating the 3-week
dosing interval.6,7
Pharmacodynamic Analysis
The effects of F on CTCs, IGF-1R expressing CTCs
and CECs were investigated. Thirty-one patients provided
blood samples (n  674) for the enumeration of these
biomarkers, including 26 patients with NSCLC. Seventeen
patients had detectable CTCs at some point during the study;
however, only one to five cells were detected in most cases,
with all but one of the patients with NSCLC having 10
CTCs at study entry. Because IGF-1R has been described as
an upstream regulator of VEGF expression,9 CECs were












Fatigue 7 5 1 13
Diarrhea 6 6 1 13
Dysgeusia 3 1 0 4
Arthralgia 2 2 0 4
Hyperglycemia 1 0 1 2
GGT elevation 0 0 1 1
Thrombocytopenia 0 0 1 1
All causality
Fatigue 14 10 5 0 29
Alopecia 10 17 0 0 27
Diarrhea 14 7 1 0 22
Nausea 10 6 3 0 19
Neuropathy 10 6 3 0 19
Arthralgia 9 9 0 0 18
Pain 6 6 2 0 14
Anorexia 8 5 0 0 13
Vomiting 7 4 2 0 13
Dysgeusia 8 3 0 0 11
Hyperglycemia 8 1 2 0 11
Hypertension 6 3 2 0 11
Anemia 3 5 3 0 11
Cough 8 2 0 0 10
Neutropenia 3 3 3 2 9
Weight loss 3 5 1 0 9
Headache 5 1 1 0 7
Chest pain 2 4 1 0 7
Vision blurred 5 0 1 0 6
Confusion 3 1 1 0 5
Thrombocytopenia 1 0 2 0 3
Infection 0 2 1 0 3
Hypotension 1 1 1 0 3
GGT, gamma glutamyl transpeptidase.
FIGURE 1. Mean (SD) plasma concentration-time profiles
of figitumumab (F) after cycles 1 and 3 of treatment.
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enumerated to evaluate any potential effect of F on this
angiogenesis marker. CECs were detected in all patients, with
a median of 52 cells per blood sample. Mean CEC counts
increased with treatment cycle but no effect of F treatment on
this pharmacodynamic parameter was observed (Figure 2).
Additional blood samples (n  351) were analyzed for
the determination of plasma levels of sIGF-1R, fIGF-1, and
IGFBP-3. An inverse correlation (Rho  0.426, p  0.03)
between baseline fIGF-1 and sIGF-1R was observed. No
correlation with demographic parameters was identified. At
low-F doses, transient decreases followed by rebound in-
creases in circulating sIGF-1R levels were observed (Figure
3). In contrast, sIGF-1R levels were maximally suppressed
for the entire dosing period at F doses levels of 3 mg/kg and
above. Meanwhile, fIGF-1 and IGFBP-3 increased in patients
in response to F treatment in a dose-dependent fashion,
although the magnitude of increase in IGFBP-3 was generally
more modest than that of fIGF-1 (Figure 3).
Efficacy
Fifteen objective responses (RECIST) were observed
(36%), including two complete responses, one in a patient
with ovarian carcinoma, and one in a patient with stage IV
NSCLC. Fourteen objective responses were seen in patients
with stages IIIB and IV NSCLC (40%). Median duration of
response was 6.5 months (range, 2–49). In addition, 16
patients with NSCLC experienced a best response of stable
disease. The median duration of disease stabilization was 2
months (range, 1–11). Six patients were stable for6 months
on single agent F maintenance therapy.
No apparent relationships between efficacy and PK,
CTC, or CEC parameters were identified. Baseline blood
samples for the analysis of plasma markers were available
from 40 patients, including 13 patients with objective re-
sponses. Patients responding to treatment at F doses 6
mg/kg seemed to have high baseline IGFBP-3 and low
fIGF-1 levels (Figure 4). As both parameters are likely
interrelated, we analyzed the ratio of fIGF-1 to IGFBP3
according to F dose (6 mg/kg versus 10–20 mg/kg) and
objective response. Of interest, patients responding to treat-
FIGURE 2. Time profiles of circulating endothelial cell
(CEC) counts in (A) all patients with providing samples for
CEC enumeration (N  22) and (B) according to figitu-
mumab (F) treatment doses 6 mg/kg (N  12) or 10 to
20 mg/kg (N  10). Data are represented as box plots (min-
imum, 25 percentile, median, 75 percentile, maximum) and
individual CEC counts. Values outside the box plots are con-
sidered outliers (smaller or larger than the minimum or max-
imum estimates).
TABLE 4. Figitumumab PK Parameters
Dose
(mg/kg)
Cycle 1 Cycle 4
RACn C1 h (mg/L)
AUC0–Day 22





0.1 2 1.40, 1.51 — 2 4.36, 1.59 — — —
0.5 3 0.533  0.212 112a 2 0.575, 0.412 0.034a 62.5a 0.56a
0.8 4 17.3, 10.3 1920  1010 2 20.3, 18.0 0.926a 1790, 2790 0.61  1.3
1.5 3 37.5  9.0 4490, 5420b 1 40.7 — 5320 1.2a
3 3 75.2  22.2 12,900  5450 2 122, 79.4 33.6, 21.8 31,200, 14,900 1.8  2.1
6 3 147  27 25,600  8830 1 327 21 44,600 1.3
10 16 255  60 52,300  14,700c 10 345  70 108  50d 87,000  15,500e 1.9  0.4e
20 5 443  85 85,300  26,000f 2 557  611 357, 207 217,000, 138,000 2.2  1.8
an  1; bn  2; cn  14; dn  7; en  9; fn  4.
C1 h, plasma concentration at 1 h post the end of infusion; Cday 22, plasma concentration at day 22 of the cycle; AUC0–day 22, area under the plasma concentration-time curve
from time 0 to day 22; n, the number of patients included in the analysis; accumulation ratio (RAC)  (cycle 4 AUC0–day 22)/(cycle 1 AUC0–day 22); AUC, area under the curve;
PK, pharmacokinetic.
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ment at F doses 6 mg/kg had fIGF-1 to IGFBP-3 ratios
lower than patients responding in the 10 and 20 mg/kg
cohorts (p  0.04) (Figure 4), suggesting that low bioactive
IGF-1 levels may be associated with response to chemother-
apy in the absence of IGF-1R blockade. Indeed, nine re-
sponses were observed in 16 patients with a fIGF-1/IGFBP3
ratio 0.018%. On the other hand, only five of 24 patients
with higher fIGF-1/IGFBP3 ratios responded (p  0.04), and
all these responders received F at 10 or 20 mg/kg. No
association of sIGF-1R levels at study entry or degree of
down-regulation post-treatment with patient response was
identified.
DISCUSSION
An every 3-week regimen of the anti-IGF-1R mono-
clonal antibody F at doses up to 20 mg/kg in combination
with paclitaxel and carboplatin was well tolerated. Grade 3
events of hyperglycemia, fatigue, diarrhea, GGT elevation,
and thrombocytopenia (one case each) were reported as
possibly related to F. Hyperglycemia seems to be character-
istic of this class of compounds,10 although contributions of
comorbid conditions, such as diabetes and steroid premedi-
cation for paclitaxel cannot be excluded. Importantly, the
event of hyperglycemia was generally manageable with an-
tidiabetic medication. Mild to moderate fatigue and sporadic
isolated GGT elevations have been observed in previous
studies of F. In contrast, severe thrombocytopenia has been
rare when F was given as single agent.6,7 This is important
because hematological toxicity has been reported to be dose
limiting for other anti-IGF-1R antibodies.11–13 It is possible
that differences in IgG subtype may be responsible for some
of these differences. F is a fully human IgG2 antibody4 and,
consequently, is expected to be a poor activator of antibody
mediated cytotoxicity and complement fixation.
The extended effective half-life of F of approximately
3 weeks at 10 and 20 mg/kg doses compares favorably with
other monoclonal antibodies in the anti-IGF-1R class.7 Mean
terminal half-lives of 4 to 11 days have been reported for
other IGF-1R monoclonal antibodies.9 These differences
could be due in part to their IgG backbone.14 PK exposure
parameters of F given in combination with paclitaxel and
FIGURE 3. Soluble insulin-like growth factor type 1 recep-
tor (IGF-1R) extracellular domain (sIGF-1R), IGF binding pro-
tein-3 (IGFBP-3), and free IGF-1 (fIGF-1) levels by figitu-
mumab (F) dose. Data are represented relative to baseline
levels.
FIGURE 4. Analysis of insulin-like growth factor (IGF) binding
protein-3 (IGFBP-3), free IGF-1 (fIGF-1) levels, and fIGF-1/IG-
FBP-3 ratio in responders (R) and nonresponders (NR) to treat-
ment, according to RECIST, at figitumumab (F) treatment
doses 6 mg/kg (N  18) or 10 to 20 mg/kg (N  22).
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carboplatin were similar to those previously observed with
single agent F,9 suggesting that the combination with pacli-
taxel/carboplatin does not significantly alter the PK properties
of F. Based on its favorable safety profile and its optimal PK
and pharmacodynamic properties, the maximal feasible dose
of 20 mg/kg has been selected for further investigation.
CTCs were detected in approximately 40% of the
patients, but the number of circulating cells was too low for
systematic analysis. CTC counts have been proposed as a
novel and noninvasive approach for pharmacodynamic stud-
ies in NSCLC and in breast and prostate cancer.5,8,15 Further
research would be required to improve the sensitivity of
current methodologies in NSCLC. Intriguingly, the median
number of CECs increased during the study in a manner
independent to F treatment. This finding may reflect a che-
motherapy effect or patient selection based on prognosis,
with those patients with a higher number of CECs receiving
a larger number of treatment cycles. In that respect, it has
been previously reported that baseline CEC counts are asso-
ciated with better patient response and outcome in
NSCLC.16 No relationship between CEC counts and re-
sponse was apparent in this study. Further research should
be undertaken to determine the prognostic value of CECs
in the treatment of NSCLC.
Finally, we found that IGF-1 bioactivity may be critical
for NSCLC response to chemotherapy and that blockade of
the IGF-1/IGF-1R interaction by F may translate to clinical
benefit, particularly in settings of high IGF-1 bioactivity.
These findings should be considered with caution due to the
small data set investigated in this study. However, these
results are consistent with previous reports associating high-
IGFBP-3 levels with longer overall, disease-free, and event-
free survival in NSCLC.17,18 Additional research will be
needed to determine the predictive value of fIGF-1 and
IGFBP-3 levels and their potential use for patient selection or
stratification in studies of anti-IGF-1R therapy. Pharmacody-
namic measures are currently underway in ongoing studies to
validate these provocative observations.19,20
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